Besides our classifier, a nonluminal disease score [64] based on percentage of ER, PR, and MKI67 tumor cells was easy, fast, and with the potential to be widely implemented to identify nonluminal disease within ER+/HER2− breast cancer when gene expression data are not available. This evidence concerns the gene ESR1 and neoplasm.